KR940005285A - 염증성 장 질환, 염증성 피부 질환 및 자반증의 예방 및 치료용 약제제조를 위한 상보적 억제제의 용도 - Google Patents

염증성 장 질환, 염증성 피부 질환 및 자반증의 예방 및 치료용 약제제조를 위한 상보적 억제제의 용도 Download PDF

Info

Publication number
KR940005285A
KR940005285A KR1019930012690A KR930012690A KR940005285A KR 940005285 A KR940005285 A KR 940005285A KR 1019930012690 A KR1019930012690 A KR 1019930012690A KR 930012690 A KR930012690 A KR 930012690A KR 940005285 A KR940005285 A KR 940005285A
Authority
KR
South Korea
Prior art keywords
prevention
treatment
use according
disease
composition
Prior art date
Application number
KR1019930012690A
Other languages
English (en)
Other versions
KR100300798B1 (ko
Inventor
뢰미슈 위르겐
파쿠에스 에릭-파울
리더 바르틀레트 로베르트
딕크나이테 게르하르트
Original Assignee
스타인, 부크
베링베르케 아크티엔게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스타인, 부크, 베링베르케 아크티엔게젤샤프트 filed Critical 스타인, 부크
Publication of KR940005285A publication Critical patent/KR940005285A/ko
Application granted granted Critical
Publication of KR100300798B1 publication Critical patent/KR100300798B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)

Abstract

본 발명은 만성 염증성 장 질환, 염증성 피부질환 및 자반증을 예방 및 치료하기 위한 상보적 억제제, 특히 C1 불활성화제 또는 인자 I 또는 H의 용도에 관한 것이다.

Description

염증성 장 질환, 염증성 피부 질환 및 자반증의 예방 및 치료용 약제 제조를 위한 상보적 억제제의 용도
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (9)

  1. 염증성 피부 질환 및 장 질환외에도 자반증의 치료 및 예방을 위한 조성물을 제조하기 위한 상보적 억제제의 용도.
  2. 제1항에 있어서, C1불활성화제, 인자 Ⅰ또는 인자 H 또는 이들의 배합물을 상보적 억제제로서 사용하는 용도.
  3. 제1항에 있어서, 크론씨 질환 또는 궤양성 결장염의 치료 및 예방을 위한 조성물을 제조하는 용도.
  4. 제2항에 있어서, 크론씨 질환 또는 궤양성 결장염의 치료 및 예방을 위한 조성물을 제조하는 용도.
  5. 제1항에 있어서, 농포성 피부병, 피부염균 또는 건선의 치료 및 예방을 위한 조성물을 제조하는 용도.
  6. 제2항에 있어서, 농포성 피부병, 피부염균 또는 건선의 치료 및 예방을 위한 조성물을 제조하는 용도.
  7. 제1항에 있어서, C1불활성화제 5내지 5000IU/kg×일 또는 인자 Ⅰ 0.005 내지 100mg/kg×일을 함유하는 조성물을 제조하는 용도.
  8. 제1항에 있어서, C1불활성화제 5 내지 5000IU/kg×일 또는 인자 Ⅰ0.01 내지 50mg/kg×일 또는 인자 H 0.01 내지 50mg/kg×일을 함유하는 조성물을 제조하는 용도.
  9. 제1항에 있어서, 정맥내, 근육내 또는 피하로 투여될 수 있는 조성물을 제조하는 용도.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019930012690A 1992-07-09 1993-07-07 보체억제제를함유하는염증성장질환염증성피부질환및자반증의예방및치료용약제학적조성물 KR100300798B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4222534A DE4222534A1 (de) 1992-07-09 1992-07-09 Verwendung von Komplement-Inhibitoren zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie von entzündlichen Darm- und Hauterkrankungen sowie Purpura
DEP4222534.5 1992-07-09

Publications (2)

Publication Number Publication Date
KR940005285A true KR940005285A (ko) 1994-03-21
KR100300798B1 KR100300798B1 (ko) 2001-10-22

Family

ID=6462826

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019930012690A KR100300798B1 (ko) 1992-07-09 1993-07-07 보체억제제를함유하는염증성장질환염증성피부질환및자반증의예방및치료용약제학적조성물

Country Status (12)

Country Link
US (1) US6248365B1 (ko)
EP (1) EP0585552B1 (ko)
JP (1) JP3776940B2 (ko)
KR (1) KR100300798B1 (ko)
AT (1) ATE231885T1 (ko)
AU (1) AU671835B2 (ko)
CA (1) CA2100212C (ko)
DE (2) DE4222534A1 (ko)
ES (1) ES2188586T3 (ko)
HU (1) HU220599B1 (ko)
MX (1) MX9304110A (ko)
TW (1) TW272940B (ko)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020082227A1 (en) * 1999-09-30 2002-06-27 Scott Henry Use of oligonucleotides for inhibition of complement activation
US6820011B2 (en) * 2001-04-11 2004-11-16 The Regents Of The University Of Colorado Three-dimensional structure of complement receptor type 2 and uses thereof
AU2003298650B2 (en) 2002-11-15 2010-03-11 Musc Foundation For Research Development Complement receptor 2 targeted complement modulators
ES2432112T3 (es) 2004-02-10 2013-11-29 The Regents Of The University Of Colorado, A Body Corporate Inhibición del factor B, de la vía alternativa del complemento y métodos relacionados
US8088579B2 (en) 2005-02-14 2012-01-03 University Of Iowa Research Foundation Complement factor H for diagnosis of age-related macular degeneration
CN103505728A (zh) * 2005-05-26 2014-01-15 科罗拉多大学评议会法人机构 用于治疗外伤性脑损伤、脊髓损伤及相关病症的补体旁路抑制
US20070196367A1 (en) * 2006-02-22 2007-08-23 Valentin Dinu Methods of preventing and treating Alzheimer's disease, age related macular degeneration and other diseases involving extra-cellular debris through the inhibition of the complement system
ES2523640T3 (es) 2006-06-21 2014-11-28 Musc Foundation For Research Development Direccionamiento del factor H del complemento para el tratamiento de enfermedades
US7329030B1 (en) 2006-08-17 2008-02-12 Augux., Ltd. Assembling structure for LED road lamp and heat dissipating module
NZ576195A (en) * 2006-10-10 2012-04-27 Az Univ Amsterdam Complement inhibition for improved nerve regeneration
WO2008140653A2 (en) 2007-03-14 2008-11-20 Taligen Therapeutics, Inc. Humaneered anti-factor b antibody
ES2475199T3 (es) 2008-09-16 2014-07-10 Imuneks Farma Ila� Sanayi Ve Ticaret A.S. Uso de antagonistas opioides para la preparación de un medicamento en el tratamiento de enfermedades degenerativas de la retina
US20100086581A1 (en) * 2008-10-07 2010-04-08 Ernest Bove Method for purpura reduction and prevention
WO2011003098A1 (en) 2009-07-02 2011-01-06 Musc Foundation For Research Development Methods of stimulating liver regeneration
EP2482816B8 (en) * 2009-10-01 2016-12-14 Imuneks Farma Ilaç Sanayi Ve Ticaret A.S. Topical compositions of naltrexone for treating skin conditions
CA2795311A1 (en) 2009-11-05 2011-05-12 Taligen Therapeutics, Inc. Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis
WO2011113641A1 (en) 2010-02-12 2011-09-22 Cemm Forschungszentrum Für Molekulare Medizin Gmbh Complement factor h for oxidative stress disease conditions
TR201002473A2 (tr) 2010-03-31 2011-09-21 Mustafa Nevzat �La� Sanay�� A.�. Herpes zoster hastalığının bır opiat reseptör antagonist kullanılarak tedavi yöntemi.
JP5986990B2 (ja) 2010-05-14 2016-09-06 ザ リージェンツ オブ ザ ユニヴァーシティ オブ コロラド，ア ボディ コーポレート 改善された補体レセプター２（ｃｒ２）ターゲティング基
MX2012014975A (es) 2010-06-22 2013-03-12 Univ Colorado Regents Anticuerpos al fragmento c3d de componente 3 de complemento.
US20120148542A1 (en) 2010-12-10 2012-06-14 Lifeline Scientific, Inc. Machine perfusion with complement inhibitors
ES2714999T3 (es) 2011-09-24 2019-05-31 Csl Behring Gmbh Terapia de combinación que usa inmunoglobulina e inhibidor de C1
AU2012318275B2 (en) 2011-12-22 2016-05-19 Csl Behring Gmbh Use of C1-inhibitor for the treatment of secondary edema of the central nervous system
WO2013177035A2 (en) 2012-05-24 2013-11-28 Alexion Pharmaceuticals, Inc. Humaneered anti-factor b antibody
AU2013302441B2 (en) 2012-08-17 2018-05-10 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for detecting complement activation
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
US8877808B2 (en) * 2012-12-06 2014-11-04 Aurin Biotech Inc. Protection against skin diseases by aurin tricarboxylic acid and its derivatives
ES2609070T3 (es) 2013-02-28 2017-04-18 Csl Behring Gmbh Agente terapéutico para el embolismo de líquido amniótico
ES2844189T3 (es) 2013-03-08 2021-07-21 Csl Behring Gmbh Tratamiento y prevención de lesiones remotas por isquemia-reperfusión
PL3013366T3 (pl) 2013-06-28 2022-01-17 Csl Behring Gmbh Terapia skojarzona z zastosowaniem inhibitora czynnika xii i inhibitora c1
CA2986957A1 (en) 2015-06-03 2016-12-08 Children's Hospital Medical Center Compositions and methods for treating neonatal biliary atresia
WO2018024873A1 (en) 2016-08-05 2018-02-08 Csl Behring Gmbh Pharmaceutical formulations of c1 esterase inhibitor
AU2017316513A1 (en) 2016-08-23 2019-03-28 Csl Behring Gmbh Method of preventing acute attacks of hereditary angioedema associated with C1 esterase inhibitor deficiency
AU2018334213A1 (en) 2017-09-15 2020-03-26 Cedars-Sinai Medical Center Methods for improving organ function in organ transplant patients
KR102060891B1 (ko) 2018-05-23 2019-12-30 유승선 가미사물탕을 유효성분으로 포함하는 색소성자반증 예방 또는 치료용 조성물
EP4247416A1 (en) 2020-11-20 2023-09-27 CSL Behring GmbH Method for treating antibody-mediated rejection
WO2023215294A1 (en) * 2022-05-02 2023-11-09 The Board Of Trustees Of The Leland Stanford Junior University Complement pathway inhibition for wound healing

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2617202A1 (de) * 1976-04-20 1977-11-03 Troponwerke Dinklage & Co Oligopeptide als komplementhemmer
DE3228502A1 (de) * 1982-07-30 1984-02-02 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung des c1-inaktivators und seine verwendung
JPH0742235B2 (ja) * 1985-11-08 1995-05-10 三共株式会社 自己免疫性疾病の予防・治療剤
US5157019A (en) * 1986-03-18 1992-10-20 Monsanto Company Serine protease inhibitors
US5166134A (en) * 1986-12-24 1992-11-24 John Lezdey Treatment of allergic rhinitis
EP0353941A3 (en) * 1988-08-02 1991-05-02 Takeda Chemical Industries, Ltd. Medicament for psoriasis containing derivatives of 3-aminopyrazolo [3,4-d]pyrimidine
US5135916A (en) * 1989-06-12 1992-08-04 Oklahoma Medical Research Foundation Inhibition of complement mediated inflammatory response
WO1992010205A1 (en) * 1990-12-06 1992-06-25 T Cell Sciences, Inc. Synergistic compositions of soluble complement receptors and compounds that inhibit complement and/or suppress immune activity

Also Published As

Publication number Publication date
CA2100212C (en) 2005-03-08
EP0585552A1 (de) 1994-03-09
EP0585552B1 (de) 2003-01-29
HU220599B1 (hu) 2002-03-28
HUT65754A (en) 1994-07-28
AU671835B2 (en) 1996-09-12
AU4180593A (en) 1994-01-13
ATE231885T1 (de) 2003-02-15
TW272940B (en) 1996-03-21
DE59310327D1 (de) 2003-03-06
ES2188586T3 (es) 2003-07-01
HU9301978D0 (en) 1993-09-28
JP3776940B2 (ja) 2006-05-24
MX9304110A (es) 1994-03-31
KR100300798B1 (ko) 2001-10-22
DE4222534A1 (de) 1994-01-13
JPH06157342A (ja) 1994-06-03
US6248365B1 (en) 2001-06-19
CA2100212A1 (en) 1994-01-10

Similar Documents

Publication Publication Date Title
KR940005285A (ko) 염증성 장 질환, 염증성 피부 질환 및 자반증의 예방 및 치료용 약제제조를 위한 상보적 억제제의 용도
KR940003555A (ko) 면역 염증성 장질환 치료용 약제학적 조성물
BR9908030A (pt) Composição farmacêutica compreendendo uma ou mais unidades de dose oralmente ministráveis, e, processos para prepará-la, para uso da mesma, e para tratar uma condição ou distúrbio médico em um indivìduo em que tratamento com um inibidor da ciclooxigenase-2 é indicado
BR0008059A (pt) Composições de valdecoxib
ES2074698T3 (es) Composicion oral para el tratamiento de enfermedades intestinales inflamatorias.
HK1028874A1 (en) Methods and compositions for inhibition of angiogenesis
BR9913157A (pt) Processos para tratar ou previnir infecção causada por pelo menos um vìrus das flaviviridae e doenças associadas com a referida infecção e infecção causada por pelo menos um vìrus do gênero hepacivìrus da flaviviridade e doenças associadas com a referida infecção, composição farmacêutica para tratar ou previnir infecções virais, e, composto
BR9205640A (pt) Dímero de apolipoproteína ai-milano, composiçao farmacológica, processo de preparaçao do dímero, uso deste na preparaçao de medicamentos e processo para o tratamento de aterosclerose e doenças cardiovasculares
MX9304435A (es) Compuesto y composicion farmaceutica para el tratamiento y la profilaxis de la obesidad o para el tratamiento de la diabetes del tipo ii.
KR920021145A (ko) 뇌 글루타메이트의 과다방출의 억제에 유용한 제형
KR940018089A (ko) 내부조직의 방사선 손상에 대한 예방 및 처치방법
KR890012644A (ko) 간 장해 치료제
NO302523B1 (no) Heterosykliske forbindelser, farmasöytiske preparater som omfatter dem, og anvendelse av forbindelsene for fremstilling av medikamenter
CA2190847A1 (en) Use of magnesium-based products for the treatment or prophylaxis of neoplastic and autoimmune diseases
KR970061244A (ko) 치매 치료용 약학 조성물
JPS5234935A (en) Medicinal composition
DK0666739T3 (da) Intravenøs opløsning som formindsker protein- og vandtab fra kroppen
WO1996022305A3 (en) Modified peptides
KR950702421A (ko) 생활성 조성물, 이것의 제조방법 및 사용방법(novel bioactive compositions, preparation and use thereof)
DE3883208D1 (de) Mittel zur behandlung von keratose.
HUP9701150A2 (hu) Azaxantonszármazékok alkalmazása látászavarok megelőzésére és kezelésére szolgáló gyógyszerkészítmények előállítására
MX9300203A (es) Compuestos policiclicos disubstituidos y composicion farmaceutica que los contiene.
KR920017668A (ko) 암 전이 억제 또는 예방 방법 및 이를 위한 제제
KR880009656A (ko) 국소 치근막 질환의 치료 또는 예방법
FR2710844B1 (fr) Composition pour le traitement ou la prévention de l'herpès.

Legal Events

Date Code Title Description
N231 Notification of change of applicant
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20100610

Year of fee payment: 10

LAPS Lapse due to unpaid annual fee